Published 8 October 2009, doi:10.1136/bmj.b3884
Cite this as: BMJ 2009;339:b3884

Research

Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States

¹ Harvard School of Public Health, Department of Health Policy and Management, Center for Health Decision Science, 718 Huntington Avenue, Boston, MA 02115, USA

Objective To assess the cost effectiveness of including preadolescent boys in a routine human papillomavirus (HPV) vaccination programme for preadolescent girls.

Design Cost effectiveness analysis from the societal perspective.

Setting United States.

Population Girls and boys aged 12 years.

Interventions HPV vaccination of girls alone and of girls and boys in the context of screening for cervical cancer.

Main outcome measure Incremental cost effectiveness ratios, expressed as cost per quality adjusted life year (QALY) gained.

Results With 75% vaccination coverage and an assumption of complete, lifelong vaccine efficacy, routine HPV vaccination of 12 year old girls was consistently less than $50 000 per QALY gained compared with screening alone. Including preadolescent boys in a routine vaccination programme for preadolescent girls resulted in higher costs and benefits and generally had cost effectiveness ratios that exceeded $100 000 per QALY across a range of HPV related outcomes, scenarios for cervical cancer screening, and assumptions of vaccine efficacy and duration. Vaccinating both girls and boys fell below a willingness to pay threshold of $100 000 per QALY only under scenarios of high, lifelong vaccine efficacy against all HPV related diseases (including other non-cervical cancers and genital warts), or scenarios of lower efficacy with lower coverage or lower vaccine costs.

Conclusions Given currently available information, including boys in an HPV vaccination programme generally exceeds conventional thresholds of good value for money, even under favourable conditions of vaccine protection and health benefits. Uncertainty still exists in many areas that can either strengthen or attenuate our findings. As new information emerges, assumptions and analyses will need to be iteratively revised to continue to inform policies for HPV vaccination.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Articles

What about male specific HPV related diseases?

Carlo Foresta, Alberto Ferlin, and Andrea Garolla
BMJ 2009 339: b4514. [Extract] [Full Text]

Inaccurate assumptions about oropharyngeal cancer

Erich M Sturgis and Kristina R Dahlstrom
BMJ 2009 339: b4525. [Extract] [Full Text]

Should HPV vaccine be given to men?

Philip E Castle and Isabel Scarinci
BMJ 2009 339: b4127. [Extract] [Full Text]

Economic evaluation of human papillomavirus vaccination in the United Kingdom

Mark Jit, Yoon Hong Choi, and W John Edmunds
BMJ 2008 337: a769. [Abstract] [Full Text] [PDF]

Related external webpages:

Listen to a podcast interview with Jane Kim

This article has been cited by other articles:

• Foresta, C., Ferlin, A., Garolla, A. (2009). What about male specific HPV related diseases?. BMJ 339: b4514-b4514 [Full text]  
• Sturgis, E. M, Dahlstrom, K. R (2009). Inaccurate assumptions about oropharyngeal cancer. BMJ 339: b4525-b4525 [Full text]  
• Castle, P. E, Scarinci, I. (2009). Should HPV vaccine be given to men?. BMJ 339: b4127-b4127 [Full text]  

Rapid Responses:

Read all Rapid Responses

HPV vaccination for girls only does not consider male specific HPV related diseases

Carlo Foresta, et al.
bmj.com, 15 Oct 2009 [Full text]

Oropharynx cancer inadequately considered in cost-analysis of HPV vaccination program.

Erich M. Sturgis, M.D., M.P.H., et al.
bmj.com, 15 Oct 2009 [Full text]

Quadrivalent HPV vaccination cost effectiveness: a missed opportunity in the UK?

Elizabeth C.F. Brown
bmj.com, 19 Oct 2009 [Full text]

Online poll

Find out more on doc2doc >>